Enliven Therapeutics (ELVN) Profit After Tax (2019 - 2026)

Enliven Therapeutics has disclosed Profit After Tax across 8 years of filings, most recently posting -$23.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$23.6 million, up 17.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.8 million (down 4.16% YoY), and the FY2025 annual result was -$103.7 million, down 16.48% from the prior year.
• Profit After Tax came in at -$23.6 million for Q1 2026 at Enliven Therapeutics, up from -$29.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$8.7 million in Q1 2022 to a low of -$29.7 million in Q4 2025.
• The 5-year median for Profit After Tax is -$20.1 million (2025), against an average of -$19.2 million.
• Across the five-year window, Profit After Tax surged 33.31% in 2022 and plunged 102.83% in 2023, its largest moves.
• Enliven Therapeutics' Profit After Tax stood at -$9.5 million in 2022, then slumped by 102.83% to -$19.4 million in 2023, then decreased by 19.67% to -$23.2 million in 2024, then fell by 27.99% to -$29.7 million in 2025, then increased by 20.36% to -$23.6 million in 2026.
• The last three Profit After Tax figures came in at -$23.6 million (Q1 2026), -$29.7 million (Q4 2025), and -$20.1 million (Q3 2025), per Business Quant data.